Table 1.
hTERT and INVAC‑1 peptides.
| Peptide | Sequence | MHC | Numbered to | Mouse strain |
|---|---|---|---|---|
| p429 | HAQCPYGVL | H2-Kb | INVAC-1 | C57BL/6 |
| p1034 | QAYRFHACVL | |||
| p660 | RPIVNMDYV | H2-Db | ||
| p1021 | QTVCTNIYKI | |||
| p196 | AYQVCGPPL | H2-Kd | INVAC-1 | BALB/c |
| p414 | RYWQMRPL | |||
| p853 | SYVQCQGI | |||
| p114 | TYVPLLGSL | |||
| p27749 | RPAEEATSL | HLA-B*0702 | hTERT | HLA-B7 |
| p35149 | RPSLTGARRL | |||
| p112350 | LPSDFKTIL | |||
| p181 | LLARCALFVL | HLA-A*0201 | INVAC-1 | HLA-A2/DR1 |
| p576 | WLMSVYVVEL | |||
| p801 | YMRQFVAHL | |||
| p959 | LLLDTRTLEV | |||
| UCP220 | KSVWSKLQSIGIRQH | HLA-DR | hTERT | |
| UCP320 | GTAFVQMPAHGLFPW | |||
| UCP420 | SLCYSILKAKNAGMS |
Following H2 and HLA‑A*0201 restricted INVAC-1 peptides have been predicted in silico; HLA‑B*0702 and HLA‑DRB1 restricted hTERT peptides were previously described.20,49,50 Peptides were used either in ELISpot assay, CBA or in vivo cytotoxicity assay according to the strains of mouse.